159 related articles for article (PubMed ID: 26208521)
21. Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts.
Wright TC; Bosch FX; Franco EL; Cuzick J; Schiller JT; Garnett GP; Meheus A
Vaccine; 2006 Aug; 24 Suppl 3():S3/251-61. PubMed ID: 16950014
[TBL] [Abstract][Full Text] [Related]
22. Testing for human papillomavirus in cervical cancer screening: a review of indications and methodology.
Nishino HT; Tambouret RH; Wilbur DC
Cancer Cytopathol; 2011 Aug; 119(4):219-27. PubMed ID: 21717588
[TBL] [Abstract][Full Text] [Related]
23. Rethinking Cervical Cancer Screening in Brazil Post COVID-19: A Global Opportunity to Adopt Higher Impact Strategies.
Ribeiro A; Corrêa F; Migowski A; Leal A; Martins S; Raiol T; Marques CP; Torres KL; Novetsky AP; Marcus JZ; Wentzensen N; Schiffman M; Rodriguez AC; Gage JC
Cancer Prev Res (Phila); 2021 Oct; 14(10):919-926. PubMed ID: 34607876
[TBL] [Abstract][Full Text] [Related]
24. [History of the development of screening tests for cervical cancer].
Herrera YA; Piña-Sánchez P
Rev Med Inst Mex Seguro Soc; 2015; 53(6):670-7. PubMed ID: 26506482
[TBL] [Abstract][Full Text] [Related]
25. New technologies and procedures for cervical cancer screening.
Cuzick J; Bergeron C; von Knebel Doeberitz M; Gravitt P; Jeronimo J; Lorincz AT; J L M Meijer C; Sankaranarayanan R; J F Snijders P; Szarewski A
Vaccine; 2012 Nov; 30 Suppl 5():F107-16. PubMed ID: 23199953
[TBL] [Abstract][Full Text] [Related]
26. Pre-vaccination prevalence of infections with 25 non-high-risk human papillomavirus types among 1,000 Slovenian women in cervical cancer screening.
Učakar V; Poljak M; Oštrbenk A; Klavs I
J Med Virol; 2014 Oct; 86(10):1772-9. PubMed ID: 24978445
[TBL] [Abstract][Full Text] [Related]
27. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial.
Lazcano-Ponce E; Lorincz AT; Cruz-Valdez A; Salmerón J; Uribe P; Velasco-Mondragón E; Nevarez PH; Acosta RD; Hernández-Avila M
Lancet; 2011 Nov; 378(9806):1868-73. PubMed ID: 22051739
[TBL] [Abstract][Full Text] [Related]
28. Human papillomavirus prevalence in paired urine and cervical samples in women invited for cervical cancer screening.
Burroni E; Bonanni P; Sani C; Lastrucci V; Carozzi F; ; Iossa A; Andersson KL; Brandigi L; Di Pierro C; Confortini M; Levi M; Boccalini S; Indiani L; Sala A; Tanini T; Bechini A; Azzari C
J Med Virol; 2015 Mar; 87(3):508-15. PubMed ID: 25418873
[TBL] [Abstract][Full Text] [Related]
29. Cervical cancer: A comprehensive approach towards extermination.
Bava SV; Thulasidasan AK; Sreekanth CN; Anto RJ
Ann Med; 2016; 48(3):149-61. PubMed ID: 26911282
[TBL] [Abstract][Full Text] [Related]
30. The next generation of cervical cancer screening programs: Making the case for risk-based guidelines.
Perkins RB; Schiffman M; Guido RS
Curr Probl Cancer; 2018 Sep; 42(5):521-526. PubMed ID: 30146347
[No Abstract] [Full Text] [Related]
31. What is needed now for successful scale-up of screening?
de Sanjose S; Holme F
Papillomavirus Res; 2019 Jun; 7():173-175. PubMed ID: 31002883
[TBL] [Abstract][Full Text] [Related]
32. Molecular diagnosis of human papillomavirus in the development of cervical cancer.
Gutiérrez-Xicoténcatl L; Plett-Torres T; Madrid-González CL; Madrid-Marina V
Salud Publica Mex; 2009; 51 Suppl 3():S479-88. PubMed ID: 20464222
[TBL] [Abstract][Full Text] [Related]
33. Considerations for HPV primary screening in lower-middle income countries.
Maza M; Gage JC
Prev Med; 2017 May; 98():39-41. PubMed ID: 28279262
[TBL] [Abstract][Full Text] [Related]
34. HPV Screening Could Cut Cervical Cancer Deaths by Up to Two-Thirds.
Harris E
JAMA; 2024 Feb; 331(5):384. PubMed ID: 38231521
[No Abstract] [Full Text] [Related]
35. Cervical cancer burden, status of implementation and challenges of cervical cancer screening in Association of Southeast Asian Nations (ASEAN) countries.
Zhao S; Huang L; Basu P; Domingo EJ; Supakarapongkul W; Ling WY; Ocviyanti D; Rezhake R; Qiao Y; Tay EH; Zhao F
Cancer Lett; 2022 Jan; 525():22-32. PubMed ID: 34728309
[TBL] [Abstract][Full Text] [Related]
36. A review of methods for detect human Papillomavirus infection.
Abreu AL; Souza RP; Gimenes F; Consolaro ME
Virol J; 2012 Nov; 9():262. PubMed ID: 23131123
[TBL] [Abstract][Full Text] [Related]
37. Commercially available molecular tests for human papillomaviruses: a global overview.
Poljak M; Oštrbenk Valenčak A; Gimpelj Domjanič G; Xu L; Arbyn M
Clin Microbiol Infect; 2020 Sep; 26(9):1144-1150. PubMed ID: 32247892
[TBL] [Abstract][Full Text] [Related]
38. Country-level correlates of cervical cancer mortality in Latin America and the Caribbean.
Pereira-Scalabrino A; Almonte M; Dos-Santos-Silva I
Salud Publica Mex; 2013; 55(1):5-15. PubMed ID: 23370254
[TBL] [Abstract][Full Text] [Related]
39. Projected cervical Cancer incidence in Swaziland using three methods and local survey estimates.
Ginindza TG; Sartorius B
BMC Cancer; 2018 Jun; 18(1):639. PubMed ID: 29879943
[TBL] [Abstract][Full Text] [Related]
40. Analysis of the effects of the age-period-birth cohort on cervical cancer mortality in the Brazilian Northeast.
Meira KC; Silva GWDS; Dos Santos J; Guimarães RM; de Souza DLB; Ribeiro GPC; Dantas ESO; Carvalho JBL; Jomar RT; Simões TC
PLoS One; 2020; 15(2):e0226258. PubMed ID: 32074101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
